SK bioscience and MSD Team Up to Enhance Ebola Vaccine Supply

SK bioscience, in collaboration with MSD and Hilleman Laboratories, is advancing the development of a vaccine for the Zaire ebolavirus, bolstered by funding from the Coalition for Epidemic Preparedness Innovations (CEPI). This partnership aims to address ongoing global health challenges posed by Ebola, particularly in areas with limited resources.

On January 22, 2026, SK bioscience announced the details of this significant collaboration. CEPI has committed up to USD 30 million to support MSD, which will allocate these funds to its development partners, including SK bioscience and Hilleman Laboratories. This financial backing will facilitate crucial research, enhance manufacturing processes, and support clinical development activities for the Zaire ebolavirus vaccine.

Strengthening Vaccine Development

The collaboration builds on MSD’s existing WHO-prequalified Zaire ebolavirus vaccine and focuses on improving its manufacturing process. This enhancement is vital, as the current vaccine requires ultra-low temperature storage, creating logistical hurdles in remote regions where Ebola outbreaks frequently occur. By increasing manufacturing yields and improving the vaccine’s thermostability, the project aims to ensure a more affordable and sustainable supply.

Hilleman Laboratories, a joint venture between MSD and the Wellcome Foundation, will spearhead the clinical development of the updated vaccine. Meanwhile, SK bioscience, in partnership with IDT Biologika, will work on refining the drug substance manufacturing process and the associated drug product. This initiative is part of a broader effort to improve vaccine accessibility, particularly in low- and middle-income countries.

As stated by Dr. Richard Hatchett, CEO of CEPI, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks.” He expressed optimism that CEPI’s support would enable a sustainable and accessible supply of the vaccine for years to come, at a more affordable price.

The Global Health Impact

Ebola, caused by the Zaire ebolavirus, continues to pose a significant threat, with an average survival rate of around 50%. Recent outbreaks in the Democratic Republic of the Congo and surrounding regions highlight the urgent need for effective vaccination strategies. The partnership among SK bioscience, MSD, and Hilleman Laboratories is critical for enhancing global defenses against this deadly pathogen.

Jaeyong Ahn, CEO of SK bioscience, emphasized the importance of global collaboration in addressing infectious diseases. He stated, “Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply.”

SK bioscience has established a commendable track record of collaboration with global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By leveraging its capabilities in development and manufacturing, the company is poised to become a key player in public health-driven vaccine initiatives.

In conclusion, this collaboration underscores the commitment of SK bioscience, MSD, and Hilleman Laboratories to combat the Zaire ebolavirus. With CEPI’s support, the project aims to enhance vaccine supply and accessibility, ultimately contributing to improved public health in vulnerable regions.